

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



APR 30 2004 2:54PM

AVENTIS US PAT DEPT

NO. 2343 P. 6/7

UNITED STATES OF AMERICA

**DECLARATION
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed
and for which a patent is sought on the invention entitled:

Indazole or Indole Derivatives, and Use Thereof in Human Medicine and More Particularly in Oncology
and the specification of which ☐ is attached hereto (Aventis Docket No. ST01021US CNT)
(check one) ☒ was filed on **January 21, 2004** as U.S. Application Number **10/761,982**
and was amended on (if applicable).
☐ was described and claimed in PCT Int'l Application Number filed on
and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification,
including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to
be material to patentability as defined in 37 C.F.R. 1.56.

☒ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at
least one other country other than the United States of America, listed below and having a filing date before that of
the application on which priority is claimed. I/We have also identified below any foreign application for patent or
inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority: **01 10118** **France** **27 July 2001**
Number Country Day/Month/Year Filed

Prior Foreign Appin(s): Number Country Day/Month/Year Filed

☐ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional
application(s) listed below:

Number Filing Date

☒ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States
application(s) or international application designating the United States listed below and, insofar as the subject
matter of each of the claims of this application is not disclosed in the prior United States application in the manner
provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose
information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which
became available between the filing date of the prior application and the national or PCT international filing date of
this application.

PCT/FR02/02638 **24 July 2002** **Pending**
Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements
and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such
willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☒ Additional names and signatures are attached.

1. Full name: **Michel TABART**

Signature: Michel Tabart

Date: February, 11th, 2004

Country of Citizenship: French

Residence: La Norville, France

(City and State/City and Country only)

P. O. Address: 3 rue Paul Langevin

91290 La Norville, France

2. Full name: **Eric BACQUÉ**

Signature: Eric Bacqué

Date: February, 11th, 2004

Country of Citizenship: French

Residence: Gif Sur Yvette

(City and State/City and Country only)

P. O. Address: 123 allée de la Clairière

91190 Gif Sur Yvette, France

3. Full name: Sylvie WENTZLERSignature: Sylvie WentzlerDate: February 10th, 2004Country of Citizenship: FrenchResidence: Fresnes, France
(City and State/City and Country only)P. O. Address: 10 avenue Garennière
94260 Fresnes, France4. Full name: Cécile COMBEAUSignature: Cécile CombeauDate: February 15th, 2004Country of Citizenship: FrenchResidence: Fontenay Aux Roses, France
(City and State/City and Country only)P. O. Address: 98 rue Boucicaut
92260 Fontenay Aux Roses, France5. Full name: Conception NEMECEKSignature: Conception NemecekDate: February 10th, 2004Country of Citizenship: FrenchResidence: Thiais, France
(City and State/City and Country only)P. O. Address: 65 rue Maurepas
94320 Thiais, France6. Full name: Patrick MAILLETSignature: Patrick MailletDate: February 10th, 2004Country of Citizenship: FrenchResidence: Fontenay Sous Bois, France
(City and State/City and Country only)P. O. Address: 87 rue Dalayrac
94120 Fontenay Sous Bois, France7. Full name: Fabienne THOMPSONSignature: Fabienne ThompsonDate: February 11th, 2004Country of Citizenship: FrenchResidence: Paris, France
(City and State/City and Country only)P. O. Address: 25 rue Cotte
75012 Paris, France

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206

P.O. Box 6800

Mail Code D-303A

Bridgewater, NJ 08807-0800

Telephone (908) 231-4803

Telefax (908) 231-2626

Aventis Docket No. ST01021US CNT



APR 30, 2004 2:54PM

AVENTIS US PAT DEPT

NO. 2343 P. 5/7

Aventis Docket No. ST01021US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **M. Tabart, et al.**

Examiner: Not Yet Assigned

Serial No.: **10/761,982**

Group Art Unit.: Not Yet Assigned

Filed: **January 21, 2004**

Title: **Indazole or Indole Derivatives, and Use Thereof
in Human Medicine and More Particularly in
Onocolgy**

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I, **Magali LE PENNEC**, an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date: January 21, 2004

By:


Magali LE PENNEC

Title:

Executive

Date:

February 9, 2004

Address correspondence and telephone calls to:
Lawrence L. Martin, Reg. No. 46,902
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626